ChatGPT Ads beta waitlist for pharma brands
ChatGPT Ads has landed in India, and ICG is running a closed 30-day beta with 20 healthcare and pharma operators before opening the service publicly. This track is built specifically for OTC and Rx-adjacent pharma brands — UCPMP 2024-clean copy from the first draft, locked-in pricing, and a dedicated pod that already knows the difference between a compliant availability claim and one that isn't.
Why we're running a closed beta first
ChatGPT Ads is a genuinely new auction, and for pharma it's a new auction with an old, well-understood problem sitting on top of it: getting conversational ad copy right without drifting into claim territory the Uniform Code for Pharmaceuticals Marketing Practices 2024 doesn't allow. Nobody in India has run enough spend through this channel yet to have real UCPMP-tested benchmarks for pharma specifically — not ICG, not any agency claiming otherwise. Anyone promising a proven pharma playbook for ChatGPT Ads this early either hasn't run the compliance review properly or hasn't run the spend.
So rather than publish a generic script and take on every pharma brand that asks, ICG is opening this the way a compliance-sensitive channel should open: a small, deliberately capped cohort, real spend, and a fixed 30-day window with a UCPMP-aware reviewer inside the workflow from day one, not bolted on at the end. Twenty operators total across healthcare and pharma, sharing one pool of slots, each account watched daily by a dedicated pod rather than glanced at once a week.
"Beta" for a pharma brand means something specific. It means the ad copy templates are still being refined against real conversational placements, that Rx-adjacent messaging is scoped conservatively to availability and information rather than clinical outcome claims until the platform's own guardrails are better understood, and that pricing is locked so an early pharma partner isn't paying for someone else's compliance learning curve. It also means ICG will say plainly in the monthly review when a format or claim style didn't clear, rather than dressing up a cautious result as a win.
The pace is honest about being early on two fronts at once — the platform itself is new, and pharma advertising rules don't get more forgiving just because the format is conversational rather than a banner or a search ad. A beta partner accepts that some copy tested in week one gets tightened by week three as the compliance read sharpens, and that this is the point of a beta, not a flaw in it.
Twenty slots, shared across the whole cohort, is what one pod can run properly with a compliance reviewer genuinely reading every piece of copy before it airs — not skimming a batch on a Friday. That discipline is non-negotiable for pharma, and it's part of why the cohort stays capped even as demand for the beta grows.
What beta partners get
Being early comes with concrete terms later cohorts won't get — and for pharma specifically, it comes with a compliance workflow built around your category from the start rather than adapted to it after the fact.
Locked pricing
Your custom-scoped rate — starting from ₹20,000/month (incl 18% GST) — is locked for the beta and carries into one full renewal cycle afterward, even if list pricing moves.
UCPMP-aware pod
A strategist, a media buyer, and a compliance reviewer who checks every piece of copy against UCPMP 2024 before it goes live — assigned to your account specifically for the beta window.
Monthly (and midpoint) review
A full performance review call at day 30, plus a lighter midpoint check-in at day 14 to catch a compliance or performance problem before it compounds.
Cohort learnings, first
Beta partners see what's working across the other accounts in the cohort — anonymised — before any of it reaches a public case study or blog post.
Rx-adjacent scoping done right
Copy for Rx-adjacent portfolios is scoped to information and availability, not clinical claims — reviewed against UCPMP by someone who reads pharma compliance for a living, not a generalist copywriter guessing.
Conversation-completion attribution
A dashboard mapped to your query or lead-tracking setup so you can see actual conversation-to-outcome performance, not proxy click metrics borrowed from search.
None of this is exclusive forever. Once the beta closes, ICG opens ChatGPT Ads as a standard pharma service line at standard pricing. The beta terms exist to reward the operators willing to move — and to have their copy reviewed at the same disciplined standard — while the channel is still unproven to most of the market, and that window closes the day the shared cohort of twenty fills.
There's a quieter benefit too: because the pod reviews pharma copy line by line rather than at volume, a claim that's borderline gets caught and rewritten inside the beta, not after a campaign has already run and drawn attention. That's a different posture than most agencies bring to pharma advertising, and it's the posture ICG wants on record before this becomes a standard service.
Who this is for and who it isn't for
ICG isn't filling slots on a first-come basis for the pharma track any more than for the rest of the cohort. The beta works because every brand in it can generate real signal — enough spend, a portfolio that can actually clear a UCPMP read, and someone who can act on what the monthly review surfaces.
A good fit
- OTC brands, or Rx-adjacent portfolios scoped to availability and information messaging
- Existing monthly digital spend of at least Rs 50,000 across any channel
- A way to track query volume, form fills, or WhatsApp leads for attribution
- A decision-maker (brand manager, marketing head, or regulatory-aware stakeholder) who can join the monthly review
- Comfortable with a compliance-first workflow — copy gets a UCPMP read before it goes live, every time
Not a fit right now
- Prescription-only claim advertising that UCPMP restricts outright — this beta doesn't attempt to route around the code
- No active digital spend or marketing budget yet
- No way to capture or track query and lead volume — the beta's value is in the attribution data
- Expecting guaranteed volume in month one — this is a new channel with a conservative compliance posture, not a proven one yet
- A portfolio ICG's compliance review can't clear for conversational ad placements at this time
If you're unsure which column your portfolio falls into, the application form is the fastest way to find out — ICG's compliance reviewer looks at every submission individually rather than filtering by a rigid checklist.
How it will work — the 30-day beta cadence
Account audit, ChatGPT Ads account provisioning, a UCPMP 2024 compliance pass on your existing brand messaging, and the first conversation-stage campaign structure built around your actual buyer or query journey.
Campaigns go live with pre-cleared copy. By day 14, your pod runs a short check-in call — what's converting, what's been flagged for a compliance tighten, and whether attribution is tracking cleanly.
Bids, creative, and intent-stage targeting adjust based on week two's data, with every revised piece of copy going back through the same compliance read before it airs.
Full 30-day performance review — cost per qualified query or lead, conversation-completion rate, a compliance summary of what was flagged and how it was resolved, and a plain-language recommendation on whether to continue at your locked rate.
Nothing here requires a long contract to find out if it works. The beta is structured to prove itself — on performance and on compliance — inside one calendar month, with an exit clause at the midpoint if it clearly isn't.
Apply for a beta slot
12 of 20 slots remain across the beta cohort. ICG reviews every application and responds within 2 business days.
Application received
ICG will review your application against the beta criteria — including a UCPMP compliance read of your portfolio — and respond within 2 business days. In the meantime, questions can go straight to WhatsApp.
WhatsApp RohitHow to apply
Fill in the form above — it takes about ninety seconds. ICG reviews applications against the qualification criteria in the section above, including a first-pass UCPMP read of your portfolio, not on a first-come basis alone, though slots do close as the shared cohort fills. You'll hear back within two business days, either with next steps to onboard or with honest feedback on why now might not be the right moment for your specific claim set.
Prefer to talk first? WhatsApp Rohit directly and ask whatever's on your mind about the compliance workflow before committing the form. There's no penalty either way — the goal is a pharma cohort that's genuinely the right fit and genuinely UCPMP-clean, not one that filled a form fastest.
